Could a simple hormone shot improve IVF live birth rates?
NCT ID NCT04064840
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a hormone drug called Decapeptyl to standard IVF treatments can increase the number of live births. About 784 women under 43 with subfertility will receive either the drug or a placebo during egg retrieval and embryo transfer. The goal is to see if this approach leads to more successful pregnancies.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Decapeptyl (gonadotropin-releasing hormone agonist)
- What this could lead to
- If successful, this could offer a simple drug adjustment to improve the chance of a live birth in IVF and frozen embryo transfers.
- What could go wrong
- This is a single-center trial, and results may not apply to all fertility clinics or patient groups. The drug may cause side effects like ovarian hyperstimulation or hormone imbalances.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 784 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2019
- Expected to finish
-
May 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 42 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
IVF Inclusion criteria: \- Women aged \<43 years at the time of IVF treatment Exclusion criteria: * Preimplantation genetic diagnosis treatment * Use of donor oocytes or donor embryos * Hydrosalpinx shown on pelvic scanning and not surgically treated * Women at risk of OHSS FET Inclusion criteria: * Women aged \<43 years at the time of IVF treatment * Replacing early cleavage embryos or blastocysts after thawing * FET in natural cycles Exclusion criteria: * Frozen early cleavage embryos thawed and cultured to blastocysts prior to transfer as requested by the patient * Preimplantation genetic diagnosis treatment * Use of donor oocytes or donor embryos * Hydrosalpinx shown on pelvic scanning and not surgically treated
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Subfertility are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Department of Obstetrics and Gynaecology
RECRUITINGHong Kong, Hong Kong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.